Endometrial integrin expression in women undergoing in vitro fertilization and the association with subsequent treatment outcome.
OBJECTIVE
To study the endometrial expression of three integrins (alpha v beta 3, alpha 4 beta 1, and alpha 1 beta 1) in women undergoing IVF-intracytoplasmic sperm injection (ICSI) treatment and assess whether they could be used to predict subsequent treatment success.Prospective observational study. Healthy volunteers in a large teaching hospital.


METHODS
Sixty-six patients attending for IVF-ICSI treatment.


METHODS
Timed endometrial biopsies were taken, during the implantation window at LH + 7-9 days, from women before IVF-ICSI treatment.


METHODS
Histological dating of endometrium and immunohistochemical staining intensity of alpha 4 beta 1, alpha v beta 3, and alpha 1 beta 1 integrins. The integrin levels were correlated with subsequent success rates.


RESULTS
There was a statistically significantly greater expression of alpha v beta 3 in the luminal epithelium of those patients who had successful treatment. However, treatment was successful in some patients with negative expression.


CONCLUSIONS
Integrins are important markers of endometrial receptivity. There is an association between an in-phase endometrial biopsy, with positive luminal alpha v beta 3 integrin expression, and subsequent treatment success. However, the clinical value of assessing the endometrium before treatment has drawbacks, and further work needs to be done before this can be considered a clinically useful test.
Thomas
Kevin
K
Reproductive Medicine Unit, Department of Obstetrics and Gynecology, Liverpool Women's Hospital, Merseyside, Liverpool, United Kingdom. kthomas@liverpool.ac.uk
Thomson
Angus
A
Wood
Simon
S
Kingsland
Charles
C
Vince
Gill
G
Lewis-Jones
Iwan
I
D000328:Adult; D004717:Endometrium / Q000378:metabolism*; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007150:Immunohistochemistry; D039222:Integrin alpha1beta1 / Q000378:metabolism*; D039041:Integrin alpha4beta1 / Q000378:metabolism*; D016023:Integrins / Q000378:metabolism*; D011446:Prospective Studies; D019030:Receptors, Vitronectin / Q000378:metabolism*; D020554:Sperm Injections, Intracytoplasmic; D016896:Treatment Outcome
D039222:Integrin alpha1beta1; D039041:Integrin alpha4beta1; D016023:Integrins; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5